The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
C. Gomez Fernandez
No relevant relationships to disclose
Y. Balagula
No relevant relationships to disclose
S. Wu
Honoraria - Novartis; Onyx; Wyeth
X. Su
No relevant relationships to disclose
D. R. Feldman
Consultant or Advisory Role - Pfizer
D. E. Rathkopf
No relevant relationships to disclose
M. E. Lacouture
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Genzyme; GlaxoSmithKline; Hana BioSciences; ImClone Systems; Lilly; Onyx; OSI Pharmaceuticals; Pfizer; Roche; Wyeth
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Genzyme; GlaxoSmithKline; Hana BioSciences; ImClone Systems; Lilly; Onyx; OSI Pharmaceuticals; Pfizer; Roche; Wyeth
Research Funding - Hana BioSciences; Onyx